Literature DB >> 29150141

Hepatocellular carcinoma in the era of immunotherapy.

Hao-Wen Sim1, Jennifer Knox2.   

Abstract

Hepatocellular carcinoma is a common malignancy which usually emerges on a background of chronic liver disease. Unfortunately, with contemporary management, patients with advanced hepatocellular carcinoma have few treatment options, and prognosis is poor. The emergence of immunotherapy has afforded new therapeutic opportunities. This article reviews the clinical evidence for immunotherapy in advanced hepatocellular carcinoma and presents ideas for future drug development.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug development; Hepatocellular carcinoma; Immunotherapy; Management; Review

Mesh：

Substances：

Year:  2017        PMID： 29150141     DOI： 10.1016/j.currproblcancer.2017.10.007

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


  49 in total

Review 1.  Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer.

Authors:  Matthew R Woeste; Anne E Geller; Robert C G Martin; Hiram C Polk
Journal:  Ann Surg Oncol       Date:  2021-01-03       Impact factor: 5.344

2.  Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.

Authors:  Rui Wang; Hui Guo; Xiaotong Tang; Tiantian Zhang; Yang Liu; Cheng Zhang; Hanbing Yu; Yumei Li
Journal:  Inflammation       Date:  2021-09-18       Impact factor: 4.092

3.  Clinical Nursing Paths Benefit Patient Outcomes Undergoing Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.

Authors:  Jing Gu; Yao Liang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-20       Impact factor: 2.650

Review 4.  Recent Advances and Perspectives on the Health Benefits of Urolithin B, A Bioactive Natural Product Derived From Ellagitannins.

Authors:  Peng Chen; Zhiei Guo; Fuchao Chen; Yue Wu; Benhong Zhou
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

5.  Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma.

Authors:  Liu Yang; Long-Fei Zeng; Guo-Qing Hong; Qing Luo; Xing Lai
Journal:  J Immunol Res       Date:  2022-07-12       Impact factor: 4.493

6.  Inhibition of mu-opioid receptor suppresses proliferation of hepatocellular carcinoma cells via CD147-p53-MAPK cascade signaling pathway.

Authors:  Jia-Jia Zhang; Chang-Geng Song; Ji-Min Dai; Xue-Qin Zhang; Peng Lin; Ling Li; Xiang-Min Yang; Zhi-Nan Chen
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 7.  Cellular based treatment modalities for unresectable hepatocellular carcinoma.

Authors:  Konstantinos Damiris; Hamza Abbad; Nikolaos Pyrsopoulos
Journal:  World J Clin Oncol       Date:  2021-05-24

Review 8.  Regulation of Glucose and Lipid Metabolism by Long Non-coding RNAs: Facts and Research Progress.

Authors:  Tie-Ning Zhang; Wei Wang; Ni Yang; Xin-Mei Huang; Chun-Feng Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-16       Impact factor: 5.555

Review 9.  Dimensions of hepatocellular carcinoma phenotypic diversity.

Authors:  Romain Désert; Natalia Nieto; Orlando Musso
Journal:  World J Gastroenterol       Date:  2018-10-28       Impact factor: 5.742

10.  Development and validation of ferroptosis-related lncRNAs signature for hepatocellular carcinoma.

Authors:  Jiaying Liang; Yaofeng Zhi; Wenhui Deng; Weige Zhou; Xuejun Li; Zheyou Cai; Zhijian Zhu; Jinxiang Zeng; Wanlan Wu; Ying Dong; Jin Huang; Yuzhuo Zhang; Shichao Xu; Yixin Feng; Fuping Ding; Jin Zhang
Journal:  PeerJ       Date:  2021-06-11       Impact factor: 2.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.